91AV

Introduction

Recent changes in the healthcare system have put a greater focus on the development and availability of generic drugs. The pharmaceutical industry has responded by exploring alternative delivery methods, creating new test designs and, most notably, developing the first American biosimilar. These advances have been met with acclaim, but they do bring new challenges. Regulatory ambiguity in testing procedures delay generic developers, and legal action from originator drug companies restricts those focusing on biosimilars. This summit will further explore the scientific necessity of this subject, while guiding experts through their collective difficulties.

Useful links

Venue

Hilton Boston Back Bay

Hilton Boston Back Bay, 40 Dalton Street, Boston, 02115, United States

Organised by

ExL Pharma

Contact information

Taryn ODonnell
ExL Pharma
+12124006229
Contact us by email

---